FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034787549> ?p ?o ?g. }

• W2034787549 endingPage "40.e2" @default.
• W2034787549 startingPage "34" @default.
• W2034787549 abstract "Objective The purpose of the 2 studies presented in this article was to determine the clinically appropriate dose of doxercalciferol capsules that is required to maintain similar intact parathyroid hormone control when converting from intravenous (IV) paricalcitol or doxercalciferol. Design Both studies were multicenter, open-label, randomized designs comprising the following 3 periods: a screening period, a 5-week run-in period, and a 5-week treatment period. Setting Dialysis centers in the United States. Patients Patients with stage 5 chronic kidney disease receiving dialysis 3 times weekly for a minimum of 6 months and with recent intact parathyroid hormone measurements between 15.9 and 63.7 pmol/L (150 to 600 pg/mL) were included. Intervention After a 5-week fixed-dose IV paricalcitol or doxercalciferol run-in period, subjects were randomized to doxercalciferol capsules for the 5-week treatment period. Conversion factors for the paricalcitol study were 0.5, 1.0, and 1.5 times the current paricalcitol dose. Conversion factors for the doxercalciferol study were 1.0, 1.5, and 2.0 times the current doxercalciferol injection dose. Results The predicted conversion factor for paricalcitol injection to doxercalciferol capsules was 0.92, whereas the factor for doxercalciferol injection to doxercalciferol capsules was 1.49. No statistically significant changes in serum calcium and phosphorus levels were found in either study. The nature of adverse events was consistent with the administration of an active vitamin D therapy to patients with chronic kidney disease receiving dialysis. Conclusion The studies demonstrate patients on dialysis can be safely and effectively converted from IV paricalcitol or doxercalciferol to oral doxercalciferol. The purpose of the 2 studies presented in this article was to determine the clinically appropriate dose of doxercalciferol capsules that is required to maintain similar intact parathyroid hormone control when converting from intravenous (IV) paricalcitol or doxercalciferol. Both studies were multicenter, open-label, randomized designs comprising the following 3 periods: a screening period, a 5-week run-in period, and a 5-week treatment period. Dialysis centers in the United States. Patients with stage 5 chronic kidney disease receiving dialysis 3 times weekly for a minimum of 6 months and with recent intact parathyroid hormone measurements between 15.9 and 63.7 pmol/L (150 to 600 pg/mL) were included. After a 5-week fixed-dose IV paricalcitol or doxercalciferol run-in period, subjects were randomized to doxercalciferol capsules for the 5-week treatment period. Conversion factors for the paricalcitol study were 0.5, 1.0, and 1.5 times the current paricalcitol dose. Conversion factors for the doxercalciferol study were 1.0, 1.5, and 2.0 times the current doxercalciferol injection dose. The predicted conversion factor for paricalcitol injection to doxercalciferol capsules was 0.92, whereas the factor for doxercalciferol injection to doxercalciferol capsules was 1.49. No statistically significant changes in serum calcium and phosphorus levels were found in either study. The nature of adverse events was consistent with the administration of an active vitamin D therapy to patients with chronic kidney disease receiving dialysis. The studies demonstrate patients on dialysis can be safely and effectively converted from IV paricalcitol or doxercalciferol to oral doxercalciferol." @default.
• W2034787549 created "2016-06-24" @default.
• W2034787549 creator A5005130427 @default.
• W2034787549 creator A5012336427 @default.
• W2034787549 creator A5013323586 @default.
• W2034787549 creator A5023599600 @default.
• W2034787549 creator A5026430959 @default.
• W2034787549 creator A5037483055 @default.
• W2034787549 creator A5046745848 @default.
• W2034787549 creator A5063370666 @default.
• W2034787549 creator A5086612247 @default.
• W2034787549 date "2012-01-01" @default.
• W2034787549 modified "2023-10-18" @default.
• W2034787549 title "Converting to Doxercalciferol Capsules From Intravenous Paricalcitol or Doxercalciferol" @default.
• W2034787549 cites W1972581770 @default.
• W2034787549 cites W1993858578 @default.
• W2034787549 cites W2018567109 @default.
• W2034787549 cites W2028302756 @default.
• W2034787549 cites W2075281659 @default.
• W2034787549 cites W2079498083 @default.
• W2034787549 cites W2126133705 @default.
• W2034787549 cites W2133134475 @default.
• W2034787549 cites W2548549197 @default.
• W2034787549 cites W28164645 @default.
• W2034787549 doi "https://doi.org/10.1053/j.jrn.2011.02.004" @default.
• W2034787549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21652220" @default.
• W2034787549 hasPublicationYear "2012" @default.
• W2034787549 type Work @default.
• W2034787549 sameAs 2034787549 @default.
• W2034787549 citedByCount "0" @default.
• W2034787549 crossrefType "journal-article" @default.
• W2034787549 hasAuthorship W2034787549A5005130427 @default.
• W2034787549 hasAuthorship W2034787549A5012336427 @default.
• W2034787549 hasAuthorship W2034787549A5013323586 @default.
• W2034787549 hasAuthorship W2034787549A5023599600 @default.
• W2034787549 hasAuthorship W2034787549A5026430959 @default.
• W2034787549 hasAuthorship W2034787549A5037483055 @default.
• W2034787549 hasAuthorship W2034787549A5046745848 @default.
• W2034787549 hasAuthorship W2034787549A5063370666 @default.
• W2034787549 hasAuthorship W2034787549A5086612247 @default.
• W2034787549 hasConcept C124490489 @default.
• W2034787549 hasConcept C126322002 @default.
• W2034787549 hasConcept C126894567 @default.
• W2034787549 hasConcept C197934379 @default.
• W2034787549 hasConcept C2778653478 @default.
• W2034787549 hasConcept C2778838027 @default.
• W2034787549 hasConcept C2779056158 @default.
• W2034787549 hasConcept C2779524405 @default.
• W2034787549 hasConcept C2779978075 @default.
• W2034787549 hasConcept C2781208988 @default.
• W2034787549 hasConcept C519063684 @default.
• W2034787549 hasConcept C71924100 @default.
• W2034787549 hasConceptScore W2034787549C124490489 @default.
• W2034787549 hasConceptScore W2034787549C126322002 @default.
• W2034787549 hasConceptScore W2034787549C126894567 @default.
• W2034787549 hasConceptScore W2034787549C197934379 @default.
• W2034787549 hasConceptScore W2034787549C2778653478 @default.
• W2034787549 hasConceptScore W2034787549C2778838027 @default.
• W2034787549 hasConceptScore W2034787549C2779056158 @default.
• W2034787549 hasConceptScore W2034787549C2779524405 @default.
• W2034787549 hasConceptScore W2034787549C2779978075 @default.
• W2034787549 hasConceptScore W2034787549C2781208988 @default.
• W2034787549 hasConceptScore W2034787549C519063684 @default.
• W2034787549 hasConceptScore W2034787549C71924100 @default.
• W2034787549 hasIssue "1" @default.
• W2034787549 hasLocation W20347875491 @default.
• W2034787549 hasLocation W20347875492 @default.
• W2034787549 hasOpenAccess W2034787549 @default.
• W2034787549 hasPrimaryLocation W20347875491 @default.
• W2034787549 hasRelatedWork W1496204266 @default.
• W2034787549 hasRelatedWork W1584512931 @default.
• W2034787549 hasRelatedWork W1813705821 @default.
• W2034787549 hasRelatedWork W2041414192 @default.
• W2034787549 hasRelatedWork W2074826032 @default.
• W2034787549 hasRelatedWork W2097260998 @default.
• W2034787549 hasRelatedWork W2181693854 @default.
• W2034787549 hasRelatedWork W2219473003 @default.
• W2034787549 hasRelatedWork W2497394583 @default.
• W2034787549 hasRelatedWork W3158204706 @default.
• W2034787549 hasVolume "22" @default.
• W2034787549 isParatext "false" @default.
• W2034787549 isRetracted "false" @default.
• W2034787549 magId "2034787549" @default.
• W2034787549 workType "article" @default.